LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Acquired by Copeland Capital Management LLC

Copeland Capital Management LLC increased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 1.0% during the third quarter, Holdings Channel reports. The institutional investor owned 1,163,392 shares of the medical instruments supplier’s stock after purchasing an additional 11,318 shares during the quarter. LeMaitre Vascular comprises 1.9% of Copeland Capital Management LLC’s holdings, making the stock its 4th biggest position. Copeland Capital Management LLC owned 0.05% of LeMaitre Vascular worth $108,068,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co grew its holdings in shares of LeMaitre Vascular by 44.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after purchasing an additional 6,875 shares in the last quarter. Quantbot Technologies LP increased its holdings in LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock valued at $487,000 after buying an additional 6,669 shares during the period. Vanguard Group Inc. increased its holdings in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the period. Quadrature Capital Ltd raised its stake in shares of LeMaitre Vascular by 129.4% in the 1st quarter. Quadrature Capital Ltd now owns 22,432 shares of the medical instruments supplier’s stock valued at $1,484,000 after buying an additional 12,654 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in shares of LeMaitre Vascular by 554.7% during the 1st quarter. Janus Henderson Group PLC now owns 55,730 shares of the medical instruments supplier’s stock worth $3,697,000 after acquiring an additional 47,218 shares during the period. 84.64% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Barrington Research reiterated an “outperform” rating and issued a $92.00 price objective on shares of LeMaitre Vascular in a research note on Friday, September 20th. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital assumed coverage on LeMaitre Vascular in a research note on Friday, August 2nd. They issued a “buy” rating and a $105.00 price target on the stock. Finally, JMP Securities increased their price objective on LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 20th. Three research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $94.67.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 3,063 shares of the firm’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the completion of the sale, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Price Performance

NASDAQ LMAT opened at $88.62 on Tuesday. The stock’s 50 day simple moving average is $89.03 and its 200 day simple moving average is $81.77. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $93.32. The firm has a market cap of $1.99 billion, a PE ratio of 58.69, a price-to-earnings-growth ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The company had revenue of $55.85 million for the quarter, compared to analysts’ expectations of $54.98 million. During the same quarter in the prior year, the business earned $0.37 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities analysts expect that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were paid a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date was Thursday, August 15th. LeMaitre Vascular’s dividend payout ratio is presently 42.38%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.